Status:
UNKNOWN
Randomized Evaluation of Shenfu Injection to Reduce Myocardial Injury
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This study aims to evaluate whether perioperative use of Shenfu Injection, as compared to placebo, could reduce infarct size assessed by cardiac magnetic resonance (CMR) in patients with acute anterio...
Detailed Description
Shenfu injection is a traditional Chinese medicine formulation containing ginseng (Panax; family: Araliaceae) and aconite (Radix aconiti lateralis preparata, Aconitum carmichaeli Debx; family: Ranuncu...
Eligibility Criteria
Inclusion
- Age ≥18 and \<75 years.
- First-time acute anterior STEMI scheduled for primary PCI.
- ST segment elevation in at least two contiguous precordial leads according to electrocardiogram (\>30 min).
- Symptoms onset ≤12 hours.
- The presence of proximal or middle left anterior descending branch (LAD) occlusion with pre-PCI TIMI flow 0 or 1 according to baseline coronary angiogram.
- Written informed consent.
Exclusion
- Cardiogenic shock, serious heart failure (Killip class III or above), malignant ventricular arrhythmia, or mechanical complications.
- Post cardiopulmonary resuscitation (CPR) (including cardioversion).
- Patients who have received thrombolytic therapy or upstream GPIIb/IIIa inhibitors (GPI).
- Uncontrolled hypertension (systolic BP ≥180 mm Hg or a diastolic BP ≥110 mmHg).
- Prior myocardial infarction, PCI or coronary artery bypass graft.
- Known severe hepatic insufficiency (AST/ALT \>3-fold the upper limit of normal value) or known renal insufficiency.
- Malignant tumor, lymphoma, HIV-positive, or cirrhosis with life expectancy \<1 year.
- Patients with active bleeding, intracranial hemorrhage, major surgery or trauma within 1 months, or ischemic stroke or transient ischemic attack (TIA) within 6 months.
- History of anemia (hemoglobin\<90g/L) or thrombocytopenia (thrombocyte\<100×109/L).
- Patients who require simultaneous intervention of left main disease during primary PCI or those with multi-vessel disease who plan to intervene in non-culprit vessels within 7 days (simultaneous or staged).
- Scheduled for CABG within one month after randomization.
- Pregnancy, lactation, or potentially fertile women.
- Patients who have known to be allergic to Shenfu Injection or its components or patients with serious adverse effect.
- Patients with contraindication to CMR (metal foreign body in the body, claustrophobia, etc.).
- Participation in other clinical trial in recent 3 months.
- Patients who cannot complete this trial or comply with the protocol.
Key Trial Info
Start Date :
July 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2022
Estimated Enrollment :
326 Patients enrolled
Trial Details
Trial ID
NCT04493840
Start Date
July 30 2020
End Date
August 31 2022
Last Update
September 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital, Capital Medical University
Beijing, China